Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa

Alshreef, A. orcid.org/0000-0003-2737-1365, MacQuilkan, K., Dawkins, B. et al. (9 more authors) (2019) Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 19. pp. 65-74. ISSN 2212-1099

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 ISPOR–The professional society for health economics and outcomes research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: transferability; model adaptation; low- and middle-income countries; early breast cancer
Dates:
  • Published (online): 13 May 2019
  • Published: 1 September 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Funding Information:
FunderGrant number
WHITE ROSE UNIVERSITY CONSORTIUMNone
Depositing User: Symplectic Sheffield
Date Deposited: 15 May 2019 11:25
Last Modified: 15 May 2019 11:25
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.vhri.2019.03.001

Share / Export

Statistics